Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Novo Nordisk's Buyback Nears Its Ceiling as FDA Orders Eye-Risk Labels Across GLP-1 Class

Drug safety Share buyback AI-generated analysis

πŸ“ˆ Novo Nordisk spent DKK 11.8 billion of its DKK 15 billion buyback authorization, purchasing 42.6 million shares since February 4.

πŸ’° The company lifted its full-year 2026 forecast with Q3 adjusted operating profit rising 27% to DKK 31.7 billion at constant exchange rates.

⚠️ The US FDA ordered new NAION risk warnings for Ozempic, Wegovy, and the wider GLP-1 class based on a review of over 134,000 patients.

πŸ‘οΈ The identified NAION risk is rare, occurring at 6.4 cases per 100,000 patient-years versus 3.8 in comparator groups.

πŸ“‰ BMO Capital raised its price target to $44.00 while maintaining a 'Market Perform' rating following the FDA order.

πŸ“ˆ Novo Nordisk stock rose 1.9% on the day of the FDA announcement, showing resilience to the new safety labels.

πŸ”¬ The company plans to present data on CagriSema and pediatric semaglutide at ObesityWeek 2026 in Washington, D.C.

πŸ›οΈ The FDA warning applies to Eli Lilly's Mounjaro and Zepbound as well, creating a class-wide regulatory environment.

Bullish Signals
  • Novo Nordisk spent DKK 11.8 billion on share buybacks, reducing its float and signaling confidence in the stock.
  • Adjusted operating profit for Q3 2026 surged 27% at constant exchange rates to reach DKK 31.7 billion.
  • BMO Capital raised its price target from $40.00 to $44.00, indicating continued analyst confidence in the company's valuation.
  • The stock gained 1.9% on the day of the FDA order, demonstrating market stability despite new safety warnings.
  • Analysts view the NAION risk as contained due to its low frequency, which supports long-term business continuity.
Risk Factors
  • The US FDA mandated new labels warning of an increased risk of NAION for Ozempic and Wegovy.
  • The FDA identified 15 probable NAION cases in a review of 126 trials, establishing a rare but serious safety signal.
  • The regulatory order applies to the entire GLP-1 class, potentially impacting market perception across all competitors.
Full Analysis
Novo Nordisk has executed a significant portion of its share repurchase program, spending approximately DKK 11.8 billion out of a total authorization of DKK 15 billion. Since February 4, the company purchased roughly 42.6 million shares at an average price of DKK 277.16, resulting in a treasury stock position equivalent to 1.3% of its share capital. This financial activity occurred alongside a notable operational update where the group lifted its full-year 2026 forecast, reporting that adjusted operating profit for the third quarter climbed 27% at constant exchange rates to reach DKK 31.7 billion. The Danish pharmaceutical giant faces new regulatory scrutiny as the US FDA ordered the addition of warnings regarding a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to its GLP-1 class products, including Ozempic and Wegovy. The FDA's decision was based on a review of 126 clinical trials involving over 134,000 patients, which identified 15 probable NAION cases. While the condition is rare, occurring at a rate of 6.4 cases per 100,000 patient-years compared to 3.8 in comparator groups, the warning requires immediate medical attention for sudden vision loss and applies broadly across the drug class. Market reaction to the FDA order has been mixed but stabilizing, with Novo Nordisk's stock rising 1.9% on the day of the announcement. Analysts from BMO Capital raised their price target from $40.00 to $44.00 while maintaining a 'Market Perform' rating, suggesting that the risk is contained due to the low frequency of the condition. The company continues to advance its pipeline, with plans to present data on CagriSema and semaglutide in children at ObesityWeek 2026, indicating ongoing development efforts despite the regulatory headwinds.